UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 001-40890
AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 83-3299164 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer
Identification No.) |
| | |
111 Sutter Street, Suite 1300,
San Francisco, California | | 94104 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area
code: (888) 669-4885
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class | | Trading Symbol (s) | | Name on each exchange on which registered |
Common Stock, $0.0001 par value per share | | AUGX | | The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒
No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes ☒ No
☐
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
There were 41,363,915 shares of the registrant’s
common stock outstanding as of November 6, 2023.
AUGMEDIX, INC.
Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2023
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
Item 1.
Financial statements.
Augmedix, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)
| |
September 30, | | |
December 31, | |
(in
thousands except share data) | |
2023 | | |
2022 | |
Assets | |
| | |
| |
Current
assets: | |
| | |
| |
Cash
and cash equivalents | |
$ | 21,593 | | |
$ | 21,251 | |
Restricted
cash | |
| 125 | | |
| 125 | |
Accounts receivable, net of allowance for doubtful accounts of $134 and $102 at September 30, 2023 and December 31, 2022, respectively | |
| 9,446 | | |
| 6,354 | |
Prepaid
expenses and other current assets | |
| 1,906 | | |
| 1,820 | |
Total
current assets | |
| 33,070 | | |
| 29,550 | |
Property
and equipment, net | |
| 3,000 | | |
| 1,573 | |
Operating
lease right of use asset | |
| 3,290 | | |
| 1,567 | |
Restricted
cash, non-current | |
| 568 | | |
| 612 | |
Deposits
and other assets | |
| 905 | | |
| 339 | |
Total
assets | |
$ | 40,833 | | |
$ | 33,641 | |
| |
| | | |
| | |
Liabilities
and Stockholders’ Equity | |
| | | |
| | |
Current
liabilities: | |
| | | |
| | |
Loan
payable, current portion | |
$ | 7,500 | | |
$ | 3,750 | |
Accounts
payable | |
| 1,816 | | |
| 1,563 | |
Accrued
expenses and other current liabilities | |
| 5,472 | | |
| 5,321 | |
Deferred
revenue | |
| 7,993 | | |
| 7,254 | |
Operating
lease liability, current portion | |
| 1,434 | | |
| 872 | |
Customer
deposits | |
| 486 | | |
| 554 | |
Total
current liabilities | |
| 24,701 | | |
| 19,314 | |
Loan
payable, net of current portion | |
| 12,608 | | |
| 11,384 | |
Operating
lease liability, net of current portion | |
| 2,079 | | |
| 968 | |
Other
liabilities | |
| 711 | | |
| 509 | |
Total
liabilities | |
| 40,099 | | |
| 32,175 | |
Commitments
and contingencies (Note 9) | |
| | | |
| | |
Stockholders’
equity: | |
| | | |
| | |
Common stock, $0.0001 par value; 500,000,000 shares authorized; 41,275,216 and 37,442,663 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| 4 | | |
| 4 | |
Additional
paid-in capital | |
| 142,077 | | |
| 127,693 | |
Accumulated
deficit | |
| (140,470 | ) | |
| (125,791 | ) |
Accumulated
other comprehensive loss | |
| (877 | ) | |
| (440 | ) |
Total
stockholders’ equity | |
| 734 | | |
| 1,466 | |
Total
liabilities and stockholders’ equity | |
$ | 40,833 | | |
$ | 33,641 | |
The accompanying notes are an integral part of these
unaudited interim condensed consolidated financial statements.
Augmedix, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(unaudited)
| |
Three
Months Ended
September 30, | | |
Nine
Months Ended
September 30, | |
(in
thousands, except share and per share data) | |
2023 | | |
2022 | | |
2023
| | |
2022 | |
Revenues | |
$ | 11,767 | | |
$ | 7,864 | | |
$ | 32,175 | | |
$ | 22,182 | |
Cost
of revenues | |
| 5,937 | | |
| 4,274 | | |
| 16,894 | | |
| 12,277 | |
Gross
profit | |
| 5,830 | | |
| 3,590 | | |
| 15,281 | | |
| 9,905 | |
Operating
expenses: | |
| | | |
| | | |
| | | |
| | |
General
and administrative | |
| 4,568 | | |
| 4,136 | | |
| 13,535 | | |
| 12,355 | |
Sales
and marketing | |
| 2,729 | | |
| 2,304 | | |
| 7,941 | | |
| 6,944 | |
Research
and development | |
| 2,936 | | |
| 2,608 | | |
| 8,236 | | |
| 7,537 | |
Total
operating expenses | |
| 10,233 | | |
| 9,048 | | |
| 29,712 | | |
| 26,836 | |
Loss
from operations | |
| (4,403 | ) | |
| (5,458 | ) | |
| (14,431 | ) | |
| (16,931 | ) |
Other
income (expenses): | |
| | | |
| | | |
| | | |
| | |
Interest
expense | |
| (642 | ) | |
| (316 | ) | |
| (1,608 | ) | |
| (1,302 | ) |
Interest
income | |
| 288 | | |
| 59 | | |
| 726 | | |
| 68 | |
Loss
on debt extinguishment | |
| — | | |
| — | | |
| — | | |
| (1,097 | ) |
Change
in fair value of warrant liability | |
| (36 | ) | |
| — | | |
| (105 | ) | |
| — | |
Other
income | |
| 470 | | |
| 244 | | |
| 907 | | |
| 452 | |
Total
other income (expenses), net | |
| 80 | | |
| (13 | ) | |
| (80 | ) | |
| (1,879 | ) |
Net
loss before income taxes | |
| (4,323 | ) | |
| (5,471 | ) | |
| (14,511 | ) | |
| (18,810 | ) |
Income
tax expense | |
| 84 | | |
| 19 | | |
| 168 | | |
| 40 | |
Net
loss | |
$ | (4,407 | ) | |
$ | (5,490 | ) | |
$ | (14,679 | ) | |
$ | (18,850 | ) |
Other
comprehensive income (loss): | |
| | | |
| | | |
| | | |
| | |
Foreign
exchange translation adjustment | |
| (106 | ) | |
| (117 | ) | |
| (437 | ) | |
| (257 | ) |
Total
comprehensive loss | |
$ | (4,513 | ) | |
$ | (5,607 | ) | |
$ | (15,116 | ) | |
$ | (19,107 | ) |
Net loss per share of common stock, basic and diluted | |
$ | (0.10 | ) | |
$ | (0.15 | ) | |
$ | (0.35 | ) | |
$ | (0.50 | ) |
Weighted average shares of common stock outstanding, basic and diluted | |
| 45,520,893 | | |
| 37,426,751 | | |
| 42,236,063 | | |
| 37,412,238 | |
The accompanying notes are an integral part of these
unaudited interim condensed consolidated financial statements.
Augmedix, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in
Stockholders’ Equity (Deficit)
(unaudited)
| |
Stockholders’
Equity | |
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
Other | | |
Total | |
| |
Common
Stock | | |
Paid-in | | |
Accumulated | | |
Comprehensive | | |
Stockholders’ | |
(in
thousands except share data) | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Loss | | |
Equity | |
Balance
at January 1, 2023 | |
| 37,442,663 | | |
$ | 4 | | |
$ | 127,693 | | |
$ | (125,791 | ) | |
$ | (440 | ) | |
$ | 1,466 | |
Exercise
of common stock options | |
| 112,252 | | |
| — | | |
| 85 | | |
| — | | |
| — | | |
| 85 | |
Stock-based
compensation expense | |
| — | | |
| — | | |
| 533 | | |
| — | | |
| — | | |
| 533 | |
Foreign
currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (33 | ) | |
| (33 | ) |
Net
loss | |
| — | | |
| — | | |
| — | | |
| (5,239 | ) | |
| — | | |
| (5,239 | ) |
Balance
at March 31, 2023 | |
| 37,554,915 | | |
$ | 4 | | |
$ | 128,311 | | |
$ | (131,030 | ) | |
$ | (473 | ) | |
$ | (3,188 | ) |
Issuance
of common stock and warrants, net of issuance costs | |
| 3,125,000 | | |
| — | | |
| 11,845 | | |
| — | | |
| — | | |
| 11,845 | |
Exercise
of common stock options | |
| 82,121 | | |
| | | |
| 93 | | |
| | | |
| | | |
| 93 | |
Stock-based
compensation | |
| — | | |
| — | | |
| 570 | | |
| — | | |
| — | | |
| 570 | |
Exercise
of common stock warrants | |
| 38,042 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
Foreign
currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (298 | ) | |
| (298 | ) |
Net
loss | |
| — | | |
| — | | |
| — | | |
| (5,033 | ) | |
| — | | |
| (5,033 | ) |
Balance
at June 30, 2023 | |
| 40,800,078 | | |
$ | 4 | | |
$ | 140,819 | | |
$ | (136,063 | ) | |
$ | (771 | ) | |
$ | 3,989 | |
Reclassification
of warrants | |
| — | | |
| — | | |
| 597 | | |
| — | | |
| — | | |
| 597 | |
Exercise
of common stock options, warrants and vesting of restricted stock units | |
| 475,138 | | |
| — | | |
| 56 | | |
| — | | |
| — | | |
| 56 | |
Stock-based
compensation expense | |
| — | | |
| — | | |
| 641 | | |
| — | | |
| — | | |
| 641 | |
Issuance
costs associated with common stock and warrants | |
| | | |
| | | |
| (36 | ) | |
| | | |
| | | |
| (36 | ) |
Foreign
currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (106 | ) | |
| (106 | ) |
Net
loss | |
| — | | |
| — | | |
| — | | |
| (4,407 | ) | |
| — | | |
| (4,407 | ) |
Balance
at September 30, 2023 | |
| 41,275,216 | | |
$ | 4 | | |
$ | 142,077 | | |
$ | (140,470 | ) | |
$ | (877 | ) | |
$ | 734 | |
Augmedix, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in
Stockholders’ Equity
(unaudited)
| |
Stockholders’ Equity | |
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
Other | | |
Total | |
| |
Common Stock | | |
Paid-in | | |
Accumulated | | |
Comprehensive | | |
Stockholders’ | |
(in thousands except share data) | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Loss | | |
Equity | |
Balance at January 1, 2022 | |
| 37,387,472 | | |
$ | 4 | | |
$ | 125,479 | | |
$ | (101,342 | ) | |
$ | (70 | ) | |
$ | 24,071 | |
Exercise of common stock options | |
| 24,015 | | |
| — | | |
| 13 | | |
| — | | |
| — | | |
| 13 | |
Stock-based compensation expense | |
| — | | |
| — | | |
| 424 | | |
| — | | |
| — | | |
| 424 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (9 | ) | |
| (9 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (6,025 | ) | |
| — | | |
| (6,025 | ) |
Balance at March 31, 2022 | |
| 37,411,487 | | |
$ | 4 | | |
$ | 125,916 | | |
$ | (107,367 | ) | |
$ | (79 | ) | |
$ | 18,474 | |
Issuance of common stock warrants | |
| — | | |
| — | | |
| 72 | | |
| — | | |
| — | | |
| 72 | |
Exercise of common stock options | |
| 12,846 | | |
| — | | |
| 6 | | |
| — | | |
| — | | |
| 6 | |
Stock-based compensation expense | |
| — | | |
| — | | |
| 491 | | |
| — | | |
| — | | |
| 491 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (131 | ) | |
| (131 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (7,335 | ) | |
| — | | |
| (7,335 | ) |
Balance at June 30, 2022 | |
| 37,424,333 | | |
$ | 4 | | |
$ | 126,485 | | |
$ | (114,702 | ) | |
$ | (210 | ) | |
$ | 11,577 | |
Exercise of common stock options | |
| 7,871 | | |
| — | | |
| 4 | | |
| — | | |
| — | | |
| 4 | |
Stock-based compensation expense | |
| — | | |
| — | | |
| 477 | | |
| — | | |
| — | | |
| 477 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| — | | |
| (117 | ) | |
| (117 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (5,490 | ) | |
| — | | |
| (5,490 | ) |
Balance at September 30, 2022 | |
| 37,432,204 | | |
$ | 4 | | |
$ | 126,966 | | |
$ | (120,192 | ) | |
$ | (327 | ) | |
$ | 6,451 | |
The accompanying notes are an integral part of these unaudited interim
condensed consolidated financial statements.
Augmedix, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited)
| |
Nine Months Ended September 30, | |
(in thousands) | |
2023 | | |
2022 | |
Cash flows from operating activities: | |
| | |
| |
Net loss | |
$ | (14,679 | ) | |
$ | (18,850 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation | |
| 792 | | |
| 607 | |
Stock-based compensation | |
| 1,735 | | |
| 1,392 | |
Non-cash interest expense | |
| 467 | | |
| 382 | |
Non-cash advertising expense | |
| — | | |
| 200 | |
Non-cash portion of loss on debt extinguishment | |
| — | | |
| 1,087 | |
Change in fair value of warrant liability | |
| 105 | | |
| — | |
Non-cash lease expenses | |
| 720 | | |
| 572 | |
Provision for bad debt | |
| 32 | | |
| 15 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (3,125 | ) | |
| 2,109 | |
Prepaid expenses and other current assets | |
| (201 | ) | |
| 101 | |
Deposits and other assets | |
| (431 | ) | |
| — | |
Accounts payable | |
| (107 | ) | |
| (111 | ) |
Accrued expenses and other liabilities | |
| 321 | | |
| 632 | |
Deferred revenue | |
| 739 | | |
| 150 | |
Customer deposit | |
| (68 | ) | |
| (37 | ) |
Lease liability | |
| (768 | ) | |
| (636 | ) |
Net cash used in operating activities | |
| (14,468 | ) | |
| (12,387 | ) |
Cash flows from investing activities: | |
| | | |
| | |
Purchase of property and equipment | |
| (1,912 | ) | |
| (816 | ) |
Net cash used in investing activities | |
| (1,912 | ) | |
| (816 | ) |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from SVB loan payable | |
| 5,000 | | |
| 15,000 | |
Repayment of Eastward loan payable | |
| — | | |
| (16,125 | ) |
Payment of financing costs | |
| (55 | ) | |
| (142 | ) |
Proceeds from issuance of common stock and warrants, net of issuance costs | |
| 11,809 | | |
| — | |
Proceeds from exercise of stock options | |
| 235 | | |
| 23 | |
Net cash provided by (used in) financing activities | |
| 16,989 | | |
| (1,244 | ) |
Effect of exchange rate changes on cash and restricted cash | |
| (311 | ) | |
| (143 | ) |
Net increase (decrease) in cash, cash equivalents and restricted cash | |
| 298 | | |
| (14,590 | ) |
Cash, cash equivalents and restricted cash at beginning of period | |
| 21,988 | | |
| 41,587 | |
Cash, cash equivalents and restricted cash at end of period | |
$ | 22,286 | | |
$ | 26,997 | |
Supplemental disclosure of cash flow information: | |
| | | |
| | |
Cash paid during the period for interest | |
$ | 1,000 | | |
$ | 815 | |
Cash paid during the period for income taxes | |
$ | 10 | | |
$ | 13 | |
Supplemental schedule of non-cash investing and financing activities: | |
| | | |
| | |
Property and equipment in accounts payable | |
$ | 375 | | |
$ | 184 | |
Operating lease right-of-use asset exchanged for operating lease liability | |
$ | 2,498 | | |
$ | — | |
Fair value of warrants issued in connection with loan | |
$ | 492 | | |
$ | 72 | |
The accompanying notes are an integral part of these
unaudited interim condensed consolidated financial statements.
Notes to Unaudited Interim Condensed Consolidated
Financial Statements
1. Organization and Nature of Business
Augmedix, Inc. (the “Company”,
“we” or “our”) was incorporated in 2013 and launched its commercial real-time, remote documentation services in
2014.
Augmedix delivers industry-leading,
ambient medical documentation and data products to healthcare systems, physician practices, hospitals, and telemedicine practitioners.
Augmedix is on a mission to help
clinicians and patients form a human connection at the point of care without the intrusion of technology. Augmedix’s products digitize
natural physician-patient conversations and convert it to medical notes in real time, which are seamlessly transferred to the Electronic
Health Record (“EHR”) system. To achieve this, the Company’s Notebuilder Platform uses Automated Speech Recognition,
Natural Language Processing, including Large Language Models, and proprietary structured data sets, supported by medical documentation
specialists.
Leveraging this platform, Augmedix’s
products relieve clinicians of administrative burden, in turn, reducing burnout and increasing both clinician and patient satisfaction.
Augmedix is headquartered in
San Francisco, CA, with offices in three (3) countries around the world.
Liquidity
The Company has historically
funded its operations primarily by debt and equity financings prior to the merger with Malo Holdings and subsequently funded its operations
through cash proceeds obtained as part of the listing on the OTC market and the listing on Nasdaq. As of September 30, 2023, the Company’s
existing sources of liquidity included cash and cash equivalents of $21.6 million, plus up to $5.0 million in incremental capital available
through the SVB Loan Agreement and an additional $5.0 million through the Equity Line of Credit with Redmile Group, LLC, which may be
utilized starting in the second half of 2024. The Company has incurred negative cash flows from operating activities and losses from operations
in the past as reflected in the accumulated deficit of $140.5 million as of September 30, 2023. The
Company has relied on debt and equity financing to fund operations to date and expects losses and negative cash flows to continue, primarily
as a result of continued research, development, and marketing efforts. The Company’s cash balance and available liquidity will provide
sufficient resources to meet working capital needs for over twelve months from the filing date of the September 30, 2023 Form
10-Q. Over the longer term, if the Company does not generate sufficient revenue from new and existing products, additional debt or equity
financing may be required along with a reduction in expenditures. Additionally, there is no assurance if the Company requires additional
future financing that such financing will be available on terms which are acceptable to it, or at all.
Risks and Uncertainties
The Company is subject to a number
of risks associated with companies at a similar stage, including dependence on key personnel, competition from similar products and larger
companies, ongoing changes within the industry, ability to obtain adequate financing to support growth, the ability to attract and retain
additional qualified personnel to manage the anticipated growth of the Company, and general economic conditions, including ongoing economic
impacts from the conflicts in Ukraine and Israel, economic volatility caused by increased interest rates, and instability within the banking
system.
2. Basis of Presentation and Summary of Significant
Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying unaudited interim
condensed consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles
generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant
to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by the Accounting
Standards Updated (“ASUs”) of the FASB. The accompanying unaudited interim condensed consolidated financial statements include
the accounts of Augmedix, Inc. and its wholly-owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited, and Augmedix
Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation.
In the opinion of management,
the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist
primarily of accruals, estimates, and assumptions that impact the financial statements) considered necessary to present fairly the Company’s
financial position as of September 30, 2023 and its results of operations for the three and nine months ended September 30, 2023 and 2022,
cash flows for nine months ended September 30, 2023 and 2022, and stockholders’ equity for the three and nine months ended September
30, 2023 and 2022. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results
that may be expected for the full year ending December 31, 2023. The unaudited interim condensed consolidated financial statements, presented
herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The condensed consolidated balance
sheet as of December 31, 2022 has been derived from the audited consolidated balance sheet as of that date. The accompanying unaudited
interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements
and related notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on April 17, 2023.
Use of Estimates
The preparation of the unaudited
interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim
condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. The Company’s
significant estimates and judgments involve the average period of benefit associated with costs capitalized to obtain a revenue contract,
incremental borrowing rate, and stock-based compensation, including the underlying fair value of the Company’s common stock for
grants issued when the Company was a private company. Actual results could differ from those estimates.
Segment Information
Operating segments are defined
as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker,
or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages
its business in one segment.
Foreign Currency Transactions, Translations and
Foreign Operations
The functional currency of the
Bangladesh and India subsidiaries are the Bangladeshi Taka and Indian Rupee, respectively. All assets and liabilities denominated in each
entity’s functional currency are translated into the United States Dollar using the exchange rate in effect as of the balance sheet
dates. Expenses are translated using the weighted average exchange rate for the reporting period. The resulting translation gains and
losses are recorded within the unaudited interim condensed consolidated statements of operations and comprehensive loss and as a separate
component of stockholders’ equity. Foreign currency transaction gains and losses are recorded within other income (expense) in the
accompanying unaudited interim condensed consolidated statements of operations and comprehensive loss. Transaction gains and losses were
$0.1 million gain for both the three months ended September 30, 2023 and 2022. Transaction gains and losses were $0.4 million gain and
$0.2 million gain for the nine months ended September 30, 2023 and 2022, respectively.
Operations outside the United
States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among
the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign
exchange controls, and restrictions on currency exchange.
All of the Company’s revenue
is generated in the United States and denominated in U.S. dollars.
Concentrations of Credit Risk and Major Customers
Financial instruments at September
30, 2023 and 2022 that potentially subject the Company to concentration of credit risk consist primarily of cash and accounts receivable.
The Company’s cash is deposited
with major financial institutions in the U.S., Bangladesh and India. At times, deposits in financial institutions located in the U.S.
may be in excess of the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation (“FDIC”).
Cash deposits at foreign financial institutions are not insured by government agencies of Bangladesh and India. To date, the Company has
not experienced any losses on its cash deposits. The Company keeps a majority of its cash in quoted and highly-liquid money market funds.
The Company’s accounts
receivable are derived from revenue from customers located in the U.S. Major customers are defined as those generating revenue in excess
of 10% of the Company’s annual revenue. The Company had three major customers during the three and nine months ended September 30,
2023. Revenues from these major customers accounted for 24%, 13% and 11% of revenue for the three months ended September 30, 2023 and
21%, 13% and 12% of revenue for the nine months ended September 30, 2023. The Company had three major customers during the three and nine
months ended September 30, 2022. Revenues from these major customers accounted for 17%, 15% and 12% of revenue for the three months ended
September 30, 2022 and 18%, 16% and 12% of revenue for the nine months ended September 30, 2022.
Two customers accounted for 10%
or more of the accounts receivable, with balances of $2.9 million and $1.9 million at September 30, 2023. Two customers account for 10%
or more of the accounts receivable, with balances of $1.4 million and $0.7 million at December 31, 2022.
Restricted Cash
Restricted cash represents amounts
held on deposit at a commercial bank used to secure the Company’s credit card facility balances, to collateralize a letter of credit
in the name of the Company’s landlord pursuant to a certain operating lease and for a post-employment savings fund established for
the benefit of eligible Bangladesh employees. The following table provides a reconciliation of the components of cash, cash equivalents
and restricted cash reported in the Company’s condensed consolidated balance sheets to the total of the amount presented in the
condensed consolidated statements of cash flows:
| |
September 30, | |
(in thousands) | |
2023 | | |
2022 | |
Cash and cash equivalents | |
$ | 21,593 | | |
$ | 26,251 | |
Restricted cash | |
| 125 | | |
| 125 | |
Restricted cash – non-current | |
| 568 | | |
| 621 | |
Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows | |
$ | 22,286 | | |
$ | 26,997 | |
Impairment of Long-Lived Assets
The Company reviews its long-lived
assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability
of assets held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated
by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets, less costs to sell. The Company did not record any expense related to asset
impairment in the nine months ended September 30, 2023 or 2022.
Revenue Recognition
ASC Topic 606, Revenue from
Contracts with Customers, outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers.
The core principle, involving a five-step process, of the revenue model is that an entity recognizes revenue to depict the transfer of
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange
for those goods or services.
The Company derives its revenue
through a stand-ready recurring subscription model. The Company enters into contracts or agreements with its customers with a general
initial term of one year. Customers are invoiced in advance and generally pay an upfront implementation fee. The upfront implementation
fee is deferred and recognized over the period the customer benefits and customer prepayments are deferred and included in the accompanying
unaudited interim condensed consolidated balance sheets in deferred revenues. Revenues are recognized over time as the professional services
are provided to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange
for those services. The customer receives the benefit of our stand-ready scribing services as we perform them.
As permitted under the practical
expedient available under ASU 2014-09, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts
with an original expected length of one year or less, (ii) contracts with variable consideration that is allocated entirely to unsatisfied
performance obligations or to a wholly unsatisfied promise accounted for under the series guidance, and (iii) contracts for which the
Company recognizes revenue for the amount at which the Company has the right to invoice for services performed.
The Company’s revenues
are earned from customers located only in the U.S. After the initial term, contracts are cancellable by the customer at their discretion
typically with a 90 day notice.
The Company determines revenue
recognition through the following steps:
|
● |
Identification of the contract, or contracts, with a customer; |
|
|
|
|
● |
Identification of the performance obligations in the contract; |
|
|
|
|
● |
Determination of the transaction price; |
|
|
|
|
● |
Allocation of the transaction price to the performance obligations in the contract; and |
|
|
|
|
● |
Recognition of revenue when, or as, the Company satisfies a performance obligation. |
Except for two U.S. state sales
tax jurisdictions, applicable taxes, including local, sales, value added tax, etc., are the responsibility of the customer to self-assess
and remit to proper tax authorities. Revenue is recognized net of any sales taxes.
Costs Capitalized to Obtain Revenue Contracts
Sales commissions earned by the
Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions
for new revenue contracts are capitalized and then amortized on a systematic basis over an estimated period of benefit that the Company
determined to be between the range of 12 to 24 months. The period of benefit was determined by taking into consideration the Company’s
customer contracts, technology, customer life, and other relevant factors. The Company periodically evaluates whether there have been
any changes in its business, market conditions, or other events which would indicate that its amortization period should be changed, or
if there are potential indicators of impairment. The current portion of capitalized sales commissions are included in prepaid expenses
and other current assets and the non-current portion is included in deposits and other assets on the accompanying unaudited interim condensed
consolidated balance sheets. Amortization expense is included in sales and marketing expenses on the accompanying unaudited interim condensed
consolidated statements of operations and comprehensive loss.
Internal-use software development costs
The Company capitalizes certain
qualifying costs incurred during the application development stage in connection with the development of its internal use software. Costs
related to preliminary project activities and post-implementation activities are expensed in research and development (“R&D”)
as incurred. R&D expenses consist primarily of employee-related costs, software-related costs, allocated overhead, and costs of outside
services used to supplement our internal staff.
Internal-use software costs of
$0.2 million and $0.4 million were capitalized in the three and nine months ended September 30, 2023, respectively. All capitalized costs
are related to costs incurred during the application development stage of software development for the Company’s platform to which
subscriptions will be sold once the software is ready for its intended use. There were no such costs capitalized during the three and
nine months ended September 30, 2022.
Capitalized internal-use software
costs are included within property and equipment, net, on the condensed consolidated balance sheets, and are amortized over the estimated
useful life of the software, which is typically three years. The related amortization expense is recognized in the condensed consolidated
statements of operations and comprehensive loss within the function that receives the benefit of the developed software. The Company will
begin to amortize the capitalized internal-use software costs once the product is ready for its intended use and goes into general commercial
release.
Contract Balances
Deferred revenue represents an
obligation to render services for which the Company has received consideration, or for which an amount of consideration is due from the
customer and the Company has an unconditional right to payment under a non-cancellable contract.
Changes in the deferred revenue
account were as follows:
(in thousands) | |
Nine Months Ended September 30, 2023 | | |
Year Ended December 31, 2022 | |
Balance, beginning of period | |
$ | 7,254 | | |
$ | 6,238 | |
Deferral of revenue | |
| 33,907 | | |
| 31,949 | |
Recognition of unearned revenue | |
| (33,168 | ) | |
| (30,933 | ) |
Balance, end of period | |
$ | 7,993 | | |
$ | 7,254 | |
Stock-Based Compensation
The Company recognizes compensation
expense for time-based restricted stock units (“RSUs”) over the requisite service period based on the fair value of RSUs on
the date of grant. The fair value of RSUs is the closing market price of Augmedix common stock on the date of grant. We recognize compensation
expense for time-based stock options based on the estimated grant-date fair value determined using the Black-Scholes valuation model over
the requisite service period.
Certain stock options include
service, market and performance conditions (“performance-based stock options”). The fair value of performance-based stock
options is estimated on the date of grant using the Monte Carlo simulation model. Awards that include performance conditions are assessed
at the end of each reporting period whether those performance conditions are met or probable of being met and involves significant judgment.
For performance-based stock options, stock-based compensation expense associated with each tranche is recognized over the longer of (i)
the expected achievement period for the operational milestone for such tranche and (ii) the expected achievement period for the related
share price milestone determined on the grant date, beginning at the point in time when the relevant operational milestone is considered
probable of being achieved. If such operational milestone becomes probable any time after the grant date, we will recognize a cumulative
catch-up expense from the grant date to that point in time. If the related share price milestone is achieved earlier than its expected
achievement period and the achievement of the related operational milestone, then the stock-based compensation expense will be recognized
over the expected achievement period for the operational milestone, which may accelerate the rate at which such expense is recognized.
The Company does not apply an
expected forfeiture rate at the time of grant and accounts for forfeitures as they occur. See Note 8 — Stock-based Compensation.
Advertising Costs
All advertising costs are expensed
as incurred and included in sales and marketing expenses. Advertising expenses incurred by the Company were $0.2 million and $0.2 million
for the three months ended September 30, 2023 and 2022, respectively, and $0.7 million and $0.7 million for the nine months ended September
30, 2023 and 2022, respectively.
Net Loss Per Share
Basic net loss per share of common stock is computed
by dividing net loss by the weighted average number of common stock outstanding during each period and pre-funded warrants outstanding
because all necessary conditions to convert into common shares were met when those warrants were issued. Diluted net loss per common stock
includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result
in the issuance of incremental common stock. Basic and diluted earnings per share were the same for both of the periods presented as the
inclusion of all potential Common Stock outstanding would have been anti-dilutive due to the fact that a net loss existed for both the
nine months ended September 30, 2023 and 2022.
The following potentially dilutive securities have
been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:
| |
September 30, 2023 | | |
September 30, 2022 | |
Common stock warrants | |
| 4,382,235 | | |
| 2,801,703 | |
Stock options | |
| 9,511,659 | | |
| 8,118,888 | |
Restricted stock units | |
| 196,688 | | |
| — | |
| |
| 14,090,582 | | |
| 10,920,591 | |
Correction of Immaterial Error Related to Prior
Periods
In the third quarter of 2022,
the Company identified an error related to its accounting for sales commissions whereby the Company should have amortized sales commissions
for new revenue contracts over the estimated period of benefit which is between the range of 12 to 24 months.
For the three and nine months
ended September 30, 2022, sales and marketing expenses were overstated by $0.1 million.
Recently Adopted Accounting Standards
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires financial assets measured
at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning
after December 15, 2022. The Company adopted this standard on January 1, 2023, and it did not have a material impact on its consolidated
financial statements upon adoption.
Recently Issued Accounting Pronouncements Not Yet
Adopted
In
August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s
Own Equity. The goal of the standard is to simplify the complexity associated with applying GAAP for certain financial instruments
with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and
derivative scope exception for contracts in an entity’s own equity. The new standard is effective for fiscal years beginning after
December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard
but does not expect it to have a material impact on its consolidated financial statements upon adoption.
3. Fair Value Measurements
Fair Value of Financial Instruments
The carrying amounts of
cash, cash equivalents, restricted cash, accounts receivable, prepaid expenses, accounts payable, and customer deposits approximate fair
value due to their short-term nature. The fair value of the warrant liability was determined based on significant inputs not observable
in the market, which represents a Level 3 measurement within the fair value hierarchy. The warrant liability was reclassified to
stockholders’ equity as of September 30, 2023.
The following tables present
information about our financial instruments that have been measured at fair value as of September 30, 2023 and December 31,
2022:
(in thousands) | |
September 30, 2023 | | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | |
Financial Assets | |
| | |
| | |
| | |
| |
Money market funds | |
$ | 18,803 | | |
$ | 18,803 | | |
$ | — | | |
$ | — | |
Total | |
$ | 18,803 | | |
$ | 18,803 | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Financial Liabilities | |
| | | |
| | | |
| | | |
| | |
Loan payable | |
$ | 20,108 | | |
$ | — | | |
$ | — | | |
$ | 20,108 | |
Total | |
$ | 20,108 | | |
$ | — | | |
$ | — | | |
$ | 20,108 | |
| |
| | | |
| | | |
| | | |
| | |
Description | |
| December 31, 2022 | | |
| (Level 1) | | |
| (Level 2) | | |
| (Level 3) | |
Financial Assets | |
| | | |
| | | |
| | | |
| | |
Money market funds | |
$ | 18,974 | | |
$ | 18,974 | | |
$ | — | | |
$ | — | |
Total | |
$ | 18,974 | | |
$ | 18,974 | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Financial Liabilities | |
| | | |
| | | |
| | | |
| | |
Loan payable | |
$ | 15,134 | | |
$ | — | | |
$ | — | | |
$ | 15,134 | |
Total | |
$ | 15,134 | | |
$ | — | | |
$ | — | | |
$ | 15,134 | |
4. Property and Equipment
Property and equipment consist
of the following:
(in thousands) | |
September 30, 2023 | | |
December 31, 2022 | |
Computer hardware, software and equipment | |
$ | 8,157 | | |
$ | 7,229 | |
Leasehold improvements | |
| 475 | | |
| 460 | |
Capitalized internal-use software costs | |
| 388 | | |
| — | |
Furniture and fixtures | |
| 81 | | |
| 73 | |
Construction in Progress | |
| 951 | | |
| 163 | |
| |
| 10,052 | | |
| 7,925 | |
Less: accumulated depreciation | |
| (7,052 | ) | |
| (6,352 | ) |
Property and equipment, net | |
$ | 3,000 | | |
$ | 1,573 | |
The Company recorded depreciation
and amortization expense of $0.3 million and $0.2 million during the three months ended September 30, 2023 and 2022, respectively, and
$0.8 million and $0.6 million during the nine months ended September 30, 2023 and 2022, respectively.
5. Accrued expenses and other current liabilities
Accrued expenses and other current
liabilities consists of the following:
(in thousands) | |
September 30, 2023 | | |
December 31, 2022 | |
Accrued compensation | |
$ | 3,163 | | |
$ | 3,587 | |
Accrued other | |
| 617 | | |
| 466 | |
Accrued vendor partner liabilities | |
| 1,187 | | |
| 871 | |
Accrued professional fees | |
| 100 | | |
| 118 | |
Accrued VAT and other taxes | |
| 404 | | |
| 279 | |
| |
$ | 5,471 | | |
$ | 5,321 | |
6. Debt
Eastward
Loan and Security Agreement
On
March 25, 2021, the Company entered into the Loan and Security Agreement (the “Eastward Loan Agreement”) with Eastward Capital
Partners (“Eastward”) to establish a loan facility that provided for borrowings in the aggregate principal amount of up to
$17.0 million, which were available to be drawn in two tranches. The first tranche of $15.0 million was funded on March 31, 2021.
Borrowings
under the Eastward Loan Agreement were repaid in full in May 2022 with the proceeds from the SVB Loan Agreement. The Company recorded
the final payment of $1.1 million as both a discount and an increase to the principal amount of the debt. The Company also capitalized
certain lender and legal costs associated with the Loan Agreement totaling $0.2 million, which were recorded as a discount to the
loan. The aggregate discount of $1.8 million was being amortized to interest expense over the repayment term of the Eastward Loan
Agreement.
SVB Loan
Agreement and Amendment
On
May 4, 2022 (the “Effective Date”), the Company and its subsidiary, Augmedix Operating Corporation (individually and collectively,
“Borrower”) entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank, a
California corporation, as lender (“SVB”). Borrower’s obligations under the SVB Loan Agreement are secured by first-priority
liens on substantially all assets of Borrower. On June 13, 2023, the Borrower entered into a First Amendment to Loan and Security
Agreement (“Amendment”) with SVB, which amends certain provisions of the SVB Loan Agreement. Under the SVB Loan Agreement,
the term loan facility’s initial stated maturity date was June 1, 2025, which was automatically extended to December 1, 2025 as
the Company achieved certain performance milestones that were a condition to such extension. The Amendment provides for further automatic
extensions of the term loan facility’s maturity date, with the possibility of automatic extension to June 1, 2027, if the Company
achieves certain equity milestones as set forth in the Amendment and certain performance milestones (including with respect to revenue
and net income (loss) as set forth in the Amendment. The Amendment also extends the stated maturity date of the revolving credit facility
from May 4, 2024 to November 4, 2024.
Under the SVB Loan Agreement,
repayment under the term loan facility was interest only until July 1, 2023, which interest only period was automatically extended to
January 1, 2024 provided the Company achieved certain performance milestones. The Amendment provides for further automatic extensions
of the amortization date, with the possibility of extension of the amortization date to July 1, 2025, if the Company achieves certain
equity milestones and certain performance milestones (including with respect to revenue and net income (loss) as set forth in the Amendment.
The Amendment provides that interest
on the borrowings under the term loan facility is payable at a floating rate per annum equal to the greater of (a) 6.00% and (b) the prime
rate plus 0.00%. Additionally, the Amendment provides that interest on the borrowings under the revolving credit facility is payable at
a floating rate per annum equal to the greater of (a) 6.50% and (b) the prime rate plus 0.50%.
The Amendment provides for a
reduction in the prepayment fee payable in connection with a prepayment by the Company of all borrowings under the term loan facility,
with the following prepayment fee payable: (a) 2.50% of the outstanding principal amount of the borrowings under the term loan facility
at the time of such prepayment if it occurs prior to the first anniversary of the Effective Date, (b) 1.50% of the outstanding principal
amount of the borrowings under the term loan facility at the time of such prepayment if it occurs on or after the first anniversary of
the effective date but prior to the second anniversary of the Effective Date, and (c) 0.50% of the outstanding principal amount of the
borrowings under the term loan facility at the time of such prepayment if it occurs on or after the second anniversary of the Effective
Date but prior to the term loan facility’s maturity date.
On September 30, 2023, the future
minimum payments required under the SVB Loan Agreement, including the final payment, are as follows as of (in thousands):
2023 (3 months remaining) | |
$ |
— | |
2024 | |
| 10,000 | |
2025 | |
| 10,000 | |
| |
$ | 20,000 | |
End of term charge | |
| 1,000 | |
| |
$ | 21,000 | |
Less unamortized debt discount | |
| (892 | ) |
Loan payable net of discount | |
$ | 20,108 | |
Less current portion | |
| 7,500 | |
Loan payable, non-current portion | |
$ | 12,608 | |
The
SVB Loan Agreement contains customary restrictions and covenants applicable to Borrower and its subsidiaries. In particular, the SVB Loan
Agreement contains a financial covenant that provides that if Borrower fails to maintain minimum cash and cash equivalents in an amount
of (a) no less than $25.0 million (prior to any Tranche B advance) and (b) $30.0 million (following any Tranche B advance),
Borrower is then required to maintain certain minimum revenue requirements as set forth in the SVB Loan Agreement, which will be measured
on a trailing 3-month basis and tested quarterly. If Borrower has failed to maintain the minimum cash and cash equivalents set forth in
the preceding sentence, in lieu of being subject to the minimum revenue requirements, Borrower has the ability to cure such failure to
maintain minimum cash and cash equivalents by delivering evidence satisfactory to SVB that Borrower has raised at least $10.0 million
in net cash proceeds from the sale of Borrower’s equity interests.
In
connection with the SVB Loan Agreement, the Company issued to SVB a warrant to purchase stock, dated as of the Effective Date (the “Warrant”),
to purchase up to 48,295 shares of the Company’s common stock, $0.0001 par value per share, exercisable at any time
for a period of approximately seven years from the Effective Date, at an exercise price of $2.38 per share, payable in
cash or on a cashless basis according to the formula set forth in the Warrant.
On June 13, 2023, in connection
with the Amendment, the Company issued to SVB a warrant to purchase up to 190,330 shares of the Company’s common stock, $0.0001
par value per share, exercisable at any time for a period of approximately seven years from the date of issuance, at an exercise price
of $4.25 per share, payable in cashless basis according to the formula set forth in the warrant. The exercise price of the warrant was
adjusted to $3.01 per share upon approval of the Company’s shareholders at the Company’s Annual Meeting of stockholders held
on July 13, 2023.
The
Company was in compliance with all covenants of the Lender on September 30, 2023 and December 31, 2022.
7. Common Stock, and Preferred Stock
Common Stock
The Company is authorized to
issue 500,000,000 shares of common stock with a par value of $0.0001 per share. Each share of common stock entitles the holder to one
vote on all matters submitted to a vote of the Company’s stockholders. Subject to preferences that may apply to any outstanding
preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company’s board of directors may
declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through September 30,
2023.
On April 19, 2023, the Company
entered into a Securities Purchase Agreement with RedCo II Master Fund, L.P. (“Redmile”) and HINSIGHT-AUGX HOLDINGS, LLC,
a wholly owned indirect subsidiary of HCA Healthcare, Inc. (the “Purchasers”), pursuant to which the Company sold to the Purchasers
for aggregate consideration of approximately $12.0 million an aggregate of 3,125,000 shares of the Company’s common stock at a purchase
price of $1.60 per share, pre-funded warrants to purchase up to 4,375,273 shares of common stock, at a price per pre-funded warrant equal
to the purchase price per share, less $0.0001, and breakeven warrants to purchase up to 1,875,069 shares of common stock, at an exercise
price of $1.75 per share, that will become exercisable on the earliest of (1) the date on which the Company closes an equity or debt financing
prior to December 31, 2025, (2) December 31, 2025, if the Company cannot provide written certification that it has achieved cash flow
break even from operations, excluding interest payments, for two out of three consecutive quarters between April 19, 2023 and December
31, 2025, on such date, (3) immediately prior to a change of control that occurs prior to December 31, 2025, and (4) the date on which
a specified Regulatory Event (as defined in the break-even warrants) occurs; provided, however, that the breakeven warrants shall terminate
on December 31, 2025 if none of the foregoing events have occurred on or prior to December 31, 2025. In no event shall the initial exercise
date be prior to the 6-month anniversary of the date of issuance, and the breakeven warrants will expire seven years following the date
of issuance. The pre-funded warrants have an exercise price of $0.0001 per pre-funded warrant share, became exercisable upon issuance
and remain exercisable until exercised in full. On June 13, 2023, the Company and Redmile entered into a separate equity line of credit,
which was subsequently approved by the Company’s stockholders on July 13, 2023. This equity line of credit permits the Company to
sell shares of its common stock having an aggregate price of up to $5,000,000 to Redmile from time to time, at a purchase price of $1.60
per share, subject to certain conditions set forth in the securities purchase agreement by and between the Company and Redmile dated as
of July 13, 2023. On May 19, 2023, the Company filed a registration statement on Form S-3 (File No. 333-272081), which was declared effective
by the SEC on May 26, 2023, which registered for resale 9,375,342 shares of the Company’s common stock.
Common Stock Warrants
At September 30, 2023, the Company
had the following warrants outstanding to acquire shares of its common stock:
Expiration Date | |
Shares
of Common Stock Issuable upon Exercise of
Warrants | | |
Exercise Price Per Warrant | |
October 25, 2024 | |
| 346,500 | | |
$ | 3.00 | |
June 11, 2025 | |
| 234 | | |
$ | 96.24 | |
November 13, 2025 | |
| 94,442 | | |
$ | 3.00 | |
July 28, 2027 | |
| 91 | | |
$ | 106.17 | |
August 28, 2028 | |
| 1,052 | | |
$ | 39.76 | |
May 4, 2029 | |
| 48,295 | | |
$ | 4.00 | |
September 2, 2029 | |
| 1,826,222 | | |
$ | 2.88 | |
April 19, 2030 | |
| 1,875,069 | | |
$ | 1.75 | |
June 13, 2030 | |
| 190,330 | | |
$ | 3.01 | |
Perpetual | |
| 4,375,273 | | |
$ | 0.0001 | |
| |
| 8,757,508 | | |
| | |
Preferred Stock
The Company is authorized to
issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors are authorized,
subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the
number of shares to be included in each series, and to fix the designation, powers, preferences, and rights of the shares of each series.
As of September 30, 2023, there were no shares of preferred stock issued or outstanding.
8. Equity Incentive Plan
At the effective date of the
Malo Holdings and Augmedix merger (the “Merger”), the Company assumed Augmedix’s 2013 Equity Incentive Plan (the “2013
Plan”). Options granted under the 2013 Plan may be incentive stock options (“ISOs”), non-qualified stock options (“NSOs”),
stock appreciation rights (“SARs”) and restricted stock awards (“RSAs”). ISOs may be granted only to Company employees
and directors. NSOs, SARs and RSAs may be granted to employees, directors, advisors, and consultants. The Company’s board of directors
has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. No shares of
restricted stock, SARs or RSUs were granted under the 2013 Plan after August 31, 2020.
Pursuant to the Merger, the Company
adopted the 2020 Equity Incentive Plan (the “2020 Plan”) which serves as successor to the 2013 Plan. The 2020 Plan authorizes
the award of stock options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards, cash awards,
and stock bonus awards. Certain awards provide for accelerated vesting in the event of a change in control. Options issued may have a
contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Company’s board of directors.
Vesting generally occurs over a period of not greater than four years.
The number of shares of common
stock reserved for issuance under the 2020 Plan increased on January 1, 2021, and will increase each anniversary thereafter through 2030
by the number of shares of common stock equal to the lesser of 5% of the total number of outstanding shares of common stock as of the
immediately preceding January 1, or a number as may be determined by the Company’s board of directors. As of September 30, 2023,
410,603 shares of common stock remained available for grant under the 2020 Plan.
The Company recorded share-based
compensation expense in the following expense categories in the condensed consolidated statements of operations and comprehensive loss
for the three and nine months ended September 30, 2023 and 2022:
Stock Options & SARs | |
Three Months Ended September 30, | | |
Nine months ended September 30, | |
(in thousands) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
General and administrative | |
$ | 271 | | |
$ | 320 | | |
$ | 783 | | |
$ | 974 | |
Sales and marketing | |
| 57 | | |
| 50 | | |
| 179 | | |
| 120 | |
Research and development | |
| 122 | | |
| 85 | | |
| 306 | | |
| 231 | |
Cost of revenues | |
| 33 | | |
| 22 | | |
| 86 | | |
| 67 | |
| |
$ | 483 | | |
$ | 477 | | |
$ | 1,354 | | |
$ | 1,392 | |
RSUs | |
Three Months Ended September 30, | | |
Nine months ended September 30, | |
(in thousands) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
General and administrative | |
$ | 154 | | |
$ | — | | |
$ | 381 | | |
$ | — | |
| |
$ | 154 | | |
$ | — | | |
$ | 381 | | |
$ | — | |
No income tax benefits have been
recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements. Stock-based
compensation costs of $4,000 and $9,000 have been capitalized as property and equipment through the three and nine months ended September
30, 2023, respectively.
The fair value of options is
estimated using the Black-Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying
ordinary shares at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each
grant of options during the nine months ended September 30, 2023 and 2022 was determined using the methods and assumptions discussed below.
|
● |
The expected term of employee options is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. |
|
● |
The expected volatility is based on historical volatility of the publicly traded common stock of a peer group of companies. |
|
● |
The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. |
| ● | The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its ordinary shares. |
For the nine months ended September
30, 2023 and 2022, the fair value of options granted was estimated using a Black-Scholes option pricing model with the following weighted
average assumptions:
| |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Expected term (in years) | |
| 5.9 | | |
| 5.9 | |
Expected volatility | |
| 57.1 | % | |
| 54.6 | % |
Risk-free rate | |
| 3.9 | % | |
| 2.0 | % |
Dividend rate | |
| | | |
| — | |
The weighted average grant date
fair value of stock option awards granted was $1.52 and $1.23 during the nine months ended September 30, 2023 and 2022, respectively.
The following table summarizes
stock option activity under the 2020 Plan for the nine months ended September 30, 2023:
Stock Option & SARs | |
Number of
Shares under
Equity Plan | | |
Weighted- Average Exercise Price per Option | | |
Weighted- Average Remaining Contractual Life (in years) | |
Outstanding at December 31, 2022 | |
| 8,234,823 | | |
$ | 1.82 | | |
| 7.7 | |
Granted | |
| 1,737,896 | | |
$ | 2.07 | | |
| | |
Exercised | |
| (290,686 | ) | |
$ | 1.33 | | |
| | |
Forfeited and expired | |
| (170,374 | ) | |
$ | 1.98 | | |
| | |
Outstanding at September 30, 2023 | |
| 9,511,659 | | |
$ | 1.92 | | |
| 7.4 | |
Exercisable at September 30, 2023 | |
| 5,832,609 | | |
$ | 1.59 | | |
| 6.7 | |
Vested and expected to vest at September 30, 2023 | |
| 9,511,659 | | |
$ | 1.92 | | |
| 7.4 | |
The intrinsic value of the options
exercised during the nine months ended September 30, 2023 was $0.6 million. The aggregate intrinsic value of options outstanding and options
exercisable as of September 30, 2023 were $30.7 million and $20.8 million, respectively. At September 30, 2023, future stock-based compensation
for options granted and outstanding of $3.4 million will be recognized over a remaining weighted-average requisite service period of 2.
2 years.
RSUs | |
Number of Shares under Equity Plan | | |
Weighted Average Grant Date Fair Value | |
Outstanding at December 31, 2022 | |
| 263,155 | | |
$ | 1.90 | |
Granted | |
| 203,988 | | |
$ | 4.45 | |
Vested | |
| (263,155 | ) | |
$ | 1.90 | |
Forfeited and expired | |
| (7,300 | ) | |
$ | 4.15 | |
Outstanding at September 30, 2023 | |
| 196,688 | | |
$ | 4.47 | |
The aggregate intrinsic value
of RSUs outstanding as of September 30, 2023, was $1.01 million. At September 30, 2023, future stock-based compensation for RSUs granted
and outstanding of $0.7 million will be recognized over a remaining weighted-average requisite service period of 1.8 years.
Performance and Market-Based
Options
In March 2021, the Company granted
727,922 stock options to the Company’s Chief Executive Officer (“CEO”) under the 2020 Plan with an exercise price of
$3.00 per share. The options vest based on the CEO’s continued service in addition to the following terms:
|
● |
317,688 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for a minimum of 20 out of 30 trading days after the Company became listed on Nasdaq. These options expire on March 3, 2031. |
|
● |
46,273 options vest in full when the closing price of the Company’s common stock reaches or exceeds $9.00 per share for 20 out of 30 trading days after the Company became listed on the New York Stock Exchange or Nasdaq. Since the listing on Nasdaq, these options expire on March 22, 2031, instead of 2026. |
|
● |
363,961 options vest in full when the closing price of the Company’s common stock reaches or exceeds $13.50 per share for 20 out of 30 trading days after the Company became listed on the New York Stock Exchange or Nasdaq. Since the listing on Nasdaq, these options expire on March 22, 2031, instead of 2026. |
The grant date fair value of
the options was determined using a Monte Carlo simulation model. The Company’s assumptions, for the options expiring on March 3,
2031, for expected volatility, closing price and risk-free rate were 50.0%, $3.00 and 0.77%, respectively. For the options expiring on
March 22, 2031, the assumptions for expected volatility, closing price and risk-free rate were 50.0%, $3.00 and 0.87%, respectively. The
aggregate estimated fair value of the options was $0.4 million. The Company recognized $0.1 million and $0.1 million in stock-based compensation
expense for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $0.1 million of unrecognized
compensation costs which the Company plans to recognize over a weighted average period of one year. If the market conditions are achieved,
any remaining unrecognized compensation cost associated with those options will be immediately recognized.
9. Commitments and Contingencies
Leases
Effective January 1, 2022, the
Company adopted ASC Topic (ASC 842) using the modified retrospective approach by applying the new standard to all leases existing on the
adoption date. The results for reporting periods beginning after January 1, 2022 are presented in accordance with ASC 842.
The Company leases its office
facilities in San Francisco, California under a non-cancelable operating lease agreement that expires February 2025. The Company entered
an office lease in India commencing January 1, 2023 which expires December 2027. In addition, the Company’s subsidiary has several
operating lease agreements for office space in Bangladesh, which expire at various dates through December 2028. The Bangladesh lease agreements
allow for early cancellation without penalty upon providing the landlord advance notice of at least nine months. The Company elected to
recognize leases less than one year under short-term lease exemption under ASC 842.
The Company subsequently decided
to enter an office lease in Bangladesh commencing May 1, 2023 which expires July 2028.
Supplemental lease information
related to leases for the periods of three and nine months ended September 30, 2022 and 2023 is as follows (in thousands):
| |
Three Months Ended September 30, | | |
Nine months ended September 30, | |
(in thousands) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating lease cost | |
$ | 309 | | |
$ | 189 | | |
$ | 855 | | |
$ | 571 | |
Short-term lease cost | |
| 107 | | |
| 88 | | |
| 282 | | |
| 263 | |
Total lease cost | |
$ | 416 | | |
$ | 277 | | |
$ | 1,137 | | |
$ | 834 | |
Other information related to
the operating lease where the Company is the lessee is as follows:
| |
Nine Months Ended September 30, 2023 | | |
Nine Months Ended September 30, 2022 | |
Weighted-average remaining lease term | |
| 3.4 | | |
| 2.5 | |
Weighted-average discount rate | |
| 6.9 | % | |
| 4.0 | % |
Supplemental cash flow information
related to the operating lease is as follows (in thousands):
| |
Nine Months Ended September 30, 2023 | | |
Nine Months Ended September 30, 2022 | |
Cash paid for operating lease liabilities | |
$ | 882 | | |
$ | 635 | |
As of September 30, 2023, the
maturities of the Company’s operating lease liabilities (excluding short-term leases) are as follows (in thousands):
2023 (remaining three months) | |
$ | 360 | |
2024 | |
| 1,464 | |
2025 | |
| 753 | |
2026 | |
| 614 | |
2027 | |
| 657 | |
Thereafter | |
| 193 | |
Total | |
$ | 4,041 | |
Less: imputed interest | |
| (528 | ) |
Operating lease liability | |
| 3,513 | |
Less: Operating lease liability, current portion | |
| (1,434 | ) |
Operating lease liability, net of current portion | |
$ | 2,079 | |
Cloud Computing Services
In June 2021, the Company entered
into a non-cancelable three-year contract to obtain cloud computing services. The minimum contractual spend over the three-year term
is $1.8 million. As of September 30, 2023, the Company has spent approximately $0.5 million against this contract.
Legal
In the normal course of business,
the Company may receive inquiries or become involved in legal disputes regarding various litigation matters. In the opinion of management,
any potential liabilities resulting from such claims would not have a material adverse effect on the Company’s condensed consolidated
financial position or results of operations or cash flows. As a result, no liability related to such claims has been recorded at September
30, 2023 or December 31, 2022.
Indemnification Agreements
From time to time, in the normal
course of business, the Company may indemnify other parties when it enters into contractual relationships, including members of the Company’s
board of directors, employees, customers, lessors and parties to other transactions with the Company. The Company may agree to hold other
parties harmless against specific losses, such as those that could arise from a breach of representation, covenant, or third-party infringement
claims. It may not be possible to determine the maximum potential amount of liability under such indemnification agreements due to the
unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Management believes
any liability arising from these agreements will not be material to the unaudited interim condensed consolidated financial statements.
As a result, no liability for these agreements has been recorded at September 30, 2023 or December 31, 2022.
10. Related Party Transactions
Operating Leases
In 2015, the Bangladesh subsidiary
entered into agreements to rent office facilities under 10-year operating lease agreements (Note 9), with a company owned by relatives
of the Company’s Director and Chief Strategy Officer. The Company paid $0.1 million to the related party during each of the three
months ended September 30, 2023 and 2022, respectively, and $0.2 million to the related party during each of the nine months ended September
30, 2023 and 2022, respectively, which is included as rent expense. At September 30, 2023, the amounts owed to the related party were
$10,000 and included in accounts payable in the accompanying consolidated balance sheet. At December 31, 2022, the amounts owed to the
related party were $4,000 and included in accounts payable in the accompanying consolidated balance sheet.
11. Employee Benefit Plan
The Company has a 401(k) plan
to provide defined contribution retirement benefits for all eligible employees. Participants may contribute a portion of their compensation
to the 401(k) plan, subject to the limitations under the Internal Revenue Code. The Company’s contributions to the 401(k) plan are
at the discretion of the Company’s board of directors. During the three months ended September 30, 2023 and 2022 the Company made
contributions of $31,000 and $33,000, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2023 and
2022, respectively, to the 401(k) plan.
Effective October 2021, the Company
established a savings fund for permanent employees of the Bangladesh subsidiary named Augmedix BD Limited Employees’ Gratuity Fund
(“Gratuity Fund”), as per local requirements. Employees will be entitled to cash benefit after completion of a minimum of
five years of service with the Company. The payment amount will be calculated on the basic pay and is payable at the rate of one month’s
basic pay for every completed year of service. The Company expensed $0.1 million and $50,000 related to the Gratuity Fund during the three
months ended September 30, 2023 and 2022, respectively, and the Company expensed $0.3 million and $0.2 million related to the Gratuity
Fund during the nine months ended September 30, 2023 and 2022, respectively. The Company has accrued $0.7 million and $0.5 million in
other liabilities in the accompanying consolidated balance sheet as of September 30, 2023 and December 31, 2022, respectively.
Similar to the Bangladesh subsidiary,
the Company established Gratuity fund for India subsidiary as per local requirements effective April 2023. The Company expensed $4,000
and $25,000 related to the Gratuity Fund during the three and nine months ended September 30, 2023, respectively. At September 30, 2023,
$24,000 was accrued in other liabilities in the accompanying consolidated balance sheet.
12. Subsequent Events
On October 17, 2023 the Company’s
board of directors approved, for a subset of employees of the Company, the issuance of 107,000 RSUs with an issuance cost of $5.72 and
61,550 SARs with an exercise price of $5.72 per share.
On October 30, 2023, SVB confirmed
and extended the interest-only period on the $20 million term loan from January 1, 2024 to July 1, 2024 as the Company met both the revenue
and net loss requirement outlined in the amendment to the SVB Loan Agreement.
On October 31, 2023, Augmedix Operating Corp., a wholly-owned subsidiary of the Company, entered into an amendment (the “Amendment”)
to an office sublease with Turo, Inc., a Delaware corporation, for the property located at 111 Sutter Street, Suite 1300, San Francisco,
California. The Amendment extends, among other things, the term of the original sublease until January 31, 2027, unless earlier terminated,
and reduced the per square foot cost of the lease.
ITEM 2. MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following discussion
and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should
be read together with the unaudited interim condensed financial statements and related notes included elsewhere in Item 1 of Part I of
this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and the related notes included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”)
on April 17, 2023.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on
Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements
relate to, among others, our plans, objectives and expectations for our business, operations and financial performance and condition,
and can be identified by terminology such as “may,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “will,” “could,”
“project,” “target,” “potential,” “continue” and similar expressions that do not relate
solely to historical matters. Forward-looking statements are based on management’s beliefs and assumptions and on information currently
available to management. Although we believe that the expectations reflected in forward-looking statements are reasonable, such statements
involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be
materially different from any future results, performance or achievements expressed or implied by forward-looking statements.
Forward-looking
statements include, but are not limited to, statements about:
|
● |
anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; |
|
● |
our ability to further penetrate our existing customer base; |
|
● |
our estimates regarding future revenues, capital requirements, general and administrative expenses, sales and marketing expenses, research and development expenses, and our need for or ability to obtain additional financing to fund our operations; |
|
● |
our intent to continue investment of additional resources in our platform infrastructure; |
|
|
|
|
● |
our expectations around our optimization efforts and investment in technology to expand the efficiency and capability of our platform, including with respect to our cost of revenues; |
|
|
|
|
● |
our ability to interoperate with the EHR systems of our customers; |
|
● |
our ability to attract and retain key personnel; |
|
● |
developments and projections relating to our competitors and our industry, including competing dictation software providers, non-real time medical note generators, and real time medical note documentation services; |
|
● |
the competition to attract and retain Medical Documentation Specialists (“MDS”); |
|
● |
our reliance on independent third parties (the “Vendors”)
who operate certain of our MDS operations centers; |
|
● |
our expectations regarding changes in regulatory requirements; |
|
● |
our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; and |
|
● |
the impact of current and future laws and regulations. |
We have based these forward-looking
statements largely on our current expectations and projections about future events and trends that we believe may affect our financial
condition, operating results, business strategy, short-term and long-term business operations and objectives, and financial needs. These
forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section
titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Moreover, we operate
in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon
forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may
not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot
guarantee future results, performance, or achievements. We undertake no obligation to update any of these forward-looking statements for
any reason after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations,
except as required by law.
You should read this Quarterly
Report on Form 10-Q and the documents that we reference herein with the understanding that our actual future results, performance, and
events and circumstances may be materially different from what we expect.
Overview
Augmedix, Inc. was incorporated
in 2013 and launched its commercial synchronous, remote, ambient documentation services in 2014. Since then, we have supplemented those
services with other, asynchronous products and data services. Our applications are accessed by clinicians through mobile devices, predominantly
smart phones. Once accessed, the client application provides clinicians with a secure communication channel to our Notebuilder Platform
which contains our note creation software that digitizes the natural conversation between clinician and patient and converts it into a
medical note. Our note creation software includes automatic speech recognition, proprietary natural language processing (“NLP”)
models, large language models (“LLMs”) and proprietary structured data sets to generate the note. The note creation process
is overseen by our Medical Documentation Specialists (“MDSs”) to provide quality assurance. Completed notes are uploaded via
integration or manually into the patient’s chart in the electronic health record (“EHR”) system. The EHR system (e.g.
Epic, Cerner) is third-party software licensed by the healthcare clinic or system to manage patient charts.
Patient care in the United
States is principally provided in ambulatory clinics, specialty care centers and hospitals. We serve several care settings, including
but not limited to, ambulatory, acute care, telemedicine and veterinary. Roughly 85% of the physicians who subscribe to our service are
employed directly by, or are affiliated with, a healthcare enterprise. The remaining 15% consists of group practices and individual practitioners.
During the third quarter
of 2023, we delivered an average of nearly 60,000 notes to our customers each week. We estimate that our products save doctors two to
three hours each day, which is time that they can redeploy to see more patients or improve their work-life balance. We believe the principal
benefits to healthcare enterprises from our products are increased clinician productivity, higher clinician and patient satisfaction,
and more accurate and comprehensive medical documentation with structured data.
The
COVID-19 pandemic and resulting safety protocols served as a catalyst for the industry’s adoption of virtual products such as ours.
The pandemic required modifications to how we deliver our service. While our general business model is for MDSs to work from centralized
operating centers, local shelter-in-place orders and safety restrictions required us to temporarily shift to work-from-home for most employees
and contracted employees. for a period of time. Further, we instituted additional administrative, technical, and physical controls to
ensure compliance with our privacy practices. In 2022, we started to shift back to central operating centers to the extent that local
conditions allowed. In the first half of 2023, we brought back to the office substantially all of our MDSs in Bangladesh and a vast majority
of our MDSs at our Vendors in India and Sri Lanka.
Due
to the success of our Bangladesh MDS operation center and the need to support additional
growth, we began the launch of our own Indian MDS operation center in the second half of 2022. In December 2022, we signed a lease for
office space and started training new MDSs and supporting clinicians onsite in February 2023. The Indian MDS operation center has grown
consistently in 2023 and now services a mid-single digit percentage point of our providers.
Our
technology vision is to automate as much of the medical note creation process as possible by combining artificial intelligence technologies,
such as automated speech recognition, natural language processing and large language models, with structured data models. While the unstructured
nature of a conversation between physician and patient creates challenges to fully automating the process, we believe that increasing
levels of automation generate significant benefits including improved operating efficiencies, higher-quality medical notes, a more uniform
level of note quality and structured medical data.
Our
automation approach is based upon our belief that harmonizing human interaction with technology generates the highest note quality. We
train our MDSs to be experts at using our technology tools to ensure it consistently and efficiently delivers high-quality, structured
medical notes.
Key metrics
We regularly review the following
key metrics to measure our performance, identify trends affecting our business, formulate financial projections, make strategic business
decisions, and assess working capital needs.
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
Key Metrics | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| |
Average clinicians in service headcount | |
| 1,650 | | |
| 1,121 | | |
| 1,517 | | |
| 1,041 | |
Average annual revenue per clinician | |
$ | 28,300 | | |
$ | 27,800 | | |
$ | 28,000 | | |
$ | 28,100 | |
Dollar-based net revenue retention | |
| 157 | % | |
| 130 | % | |
| 147 | % | |
| 130 | % |
Average Clinicians in
Service Headcount: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using
our services. We average the month end number of clinicians in service for all months in the measurement period and the number of clinicians
in service at the end of the month immediately preceding the measurement period. We believe growth in the average number of clinicians
in service is a key indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.
Most of our customer contracts contain minimum service levels that range from a low of 60 hours per month to a high of 200 hours per month.
Higher hours per month equate to higher revenue per clinician. The average number of clinicians in service grew 47% to 1,650 from 1,121
for the three months ended September 30, 2023 and 2022, respectively, and grew 46% to 1,517 from 1,041 for the nine months ended September
30, 2023 and 2022, respectively.
Average Annual Revenue
Per Clinician: Average revenue per clinician is determined as total revenue, excluding Data Services revenue, recognized during the
period presented divided by the average number of clinicians in service during that same period. Using the number of clinicians in service
at the end of each month, we derive an average number of clinicians in service for the periods presented. The average annual revenue per
clinician will vary based upon minimum hours of service requested by clinicians, pricing, and our product mix. The average annual revenue
per clinician increased to $28,300 in the three months ended September 30, 2023, slightly growing from $27,800 in the three months ended
September 30, 2022. The average annual revenue per clinician decreased to $28,000 in the nine months ended September 30, 2023, marginally
down from $28,100 in the nine months ended September 30, 2022.
Dollar-Based Net Revenue
Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently
employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises
as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or
current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing
twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention
is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer
base through expansion of users, products and price, as well as our ability to retain existing customers. Our annual dollar-based net
revenue retention increased to 157% in three months ended September 30, 2023 compared to 130% in the three months ended September 30,
2022. Growth from existing clients has historically represented a majority of our total revenue growth. Our annual dollar-based net revenue
retention increased to 147% in the nine months ended September 30, 2023, up from 130% in nine months ended September 30, 2022.
Components of Results of Operations
Revenues
Our revenues primarily consist
of service fees we charge customers to subscribe to our ambient medical documentation and clinical support solutions. We generate subscription
fees pursuant to contracts that typically have initial terms of one year, automatically renew after the initial term and are typically
subject to a 90 day cancellation notice after the initial one year term. Customer attrition, as it pertains to our Enterprise clients
is infrequent. In fiscal 2022, 2021, 2019, 2018, and 2017, we did not lose any of our Health Enterprise clients. We lost one Health Enterprise,
client, one of our smallest clients, in the first quarter of 2023. We lost three Health Enterprise clients in fiscal 2020, with the economic
strain caused by the COVID-19 pandemic on those clients being the main contributing factor for these losses, but we also won three new
Health Enterprise clients during the same year. Subscription revenue is driven primarily by the number of clinicians using our services,
the minimum number of hours contracted per month, and the contracted monthly price. We typically invoice customers one to three months
in advance for subscriptions to our services. For customers who use more than the minimum number of monthly hours, we have the ability
to bill for the additional hours utilized at a prescribed contractual price. We also perform upfront implementation services such as Wi-Fi
assessments of the clinician’s facilities, shipping devices and accessories to the clinician, testing, selecting and assigning MDSs,
obtaining EHR systems credentials for MDSs, and clinician orientation. Revenues associated with implementation efforts are deferred until
we go live with our service and then recognized ratably over the initial term of the contract.
Cost of Revenues and
Gross Profit
Cost
of Revenues. Our cost of revenues primarily consists of the cost of MDSs, some of whom are employees of our Vendors and some of whom
are our employees, their direct supervisors, clinician support, and technical support. Cost of revenues also consists of infrastructure
costs to operate our SaaS-based platform such as hosting fees and fees paid to various third-party partners for access to their technology,
plus hardware depreciation and cost of shipping for the devices and accessories we provide to our clinicians.
Gross
Profit. Our gross profit is calculated by subtracting our cost of revenues from revenues. Gross margin is expressed as
a percentage of total revenues. Our gross profit may fluctuate from period to period as revenues fluctuate and as a result of the mix
of MDS centers from which service is provided, operational efficiencies, product mix, and changes to our technology expenses and customer
support.
Our
gross profit varies by MDS center. We plan to focus on and grow the operations of the MDS centers with the best quality and highest gross
margin. We intend to continue to invest additional resources in our platform infrastructure. We will also continue to invest in technology
innovation, such as Notebuilder, to reduce the level of effort required by MDSs and the number of MDSs needed overall to deliver our services.
We expect these optimization efforts and our investment in technology to expand the efficiency and capability of our platform, enabling
us to improve our gross margin over time. The level and timing of investment in these areas, the mix of MDS centers, and the mix of our
products, could affect our cost of revenues in the future.
General and Administrative
Expenses
General
and administrative expenses consist primarily of employee compensation costs for operations management, finance, accounting, information
technology, compliance, legal and human resources personnel, board of director costs, and our business support team in Bangladesh. In
addition, general and administrative expenses include non-personnel costs, such as facilities, legal, accounting, software implementation
fees, compliance testing, investor relations, insurance premiums, and other professional fees, as well as other supporting corporate expenses
not allocated to other departments. We expect our general and administrative expenses will increase in absolute dollars as our business
grows, but we expect general and administrative expenses to decrease as a percentage of revenues in the coming years.
Sales and Marketing
Expenses
Sales
and marketing expenses consist primarily of employee compensation costs related to sales and marketing, including salaries, benefits,
bonuses, and stock-based compensation, costs of general marketing activities and promotional activities, travel-related expenses, and
allocated overhead. Sales and marketing expenses also include onboarding costs for new clinicians and costs for advertising and other
marketing activities. Advertising is expensed as incurred. We expect our sales and marketing expenses will increase in absolute dollars
as we expand our sales and marketing efforts and onboarding capacity.
Research and Development
Expenses
Research
and development expenses consist of costs for the design, development, testing, and enhancement of our products and services and are generally
expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation
for our development personnel. Research and development expenses also include direct MDS training costs, product management, third-party
partner fees, and third-party consulting fees. We expect our research and development expenses will increase in absolute dollars as our
business grows.
Interest Expense,
net
Interest
expense, net, consists primarily of the interest incurred on our debt obligations and the non-cash interest expense associated with the
amortization of debt discounts. Interest expense is offset by any interest income we earn on our cash balances held in our interest-bearing
savings account or money market funds.
Other Income (Expense)
Other
income (expenses) consists primarily of Bangladesh government grant income and also foreign currency gains and losses due to exchange
rate fluctuations on transactions denominated in a currency other than our functional currency.
The following table summarizes
the results of our operations for the periods presented:
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
(in thousands, except share and per share data) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenues | |
$ | 11,767 | | |
$ | 7,864 | | |
$ | 32,175 | | |
$ | 22,182 | |
Cost of revenues | |
| 5,937 | | |
| 4,274 | | |
| 16,894 | | |
| 12,277 | |
Gross profit | |
| 5,830 | | |
| 3,590 | | |
| 15,281 | | |
| 9,905 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
General and administrative | |
| 4,568 | | |
| 4,136 | | |
| 13,535 | | |
| 12,355 | |
Sales and marketing | |
| 2,729 | | |
| 2,304 | | |
| 7,941 | | |
| 6,944 | |
Research and development | |
| 2,936 | | |
| 2,608 | | |
| 8,236 | | |
| 7,537 | |
Total operating expenses | |
| 10,233 | | |
| 9,048 | | |
| 29,712 | | |
| 26,836 | |
Loss from operations | |
| (4,403 | ) | |
| (5,458 | ) | |
| (14,431 | ) | |
| (16,931 | ) |
Other income (expenses): | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (642 | ) | |
| (316 | ) | |
| (1,608 | ) | |
| (1,302 | ) |
Interest income | |
| 288 | | |
| 59 | | |
| 726 | | |
| 68 | |
Loss on extinguishment | |
| — | | |
| — | | |
| — | | |
| (1,097 | ) |
Change in fair value of warrant liability | |
| (36 | ) | |
| — | | |
| (105 | ) | |
| | |
Other income | |
| 470 | | |
| 244 | | |
| 907 | | |
| 452 | |
Net loss before income tax | |
| (4,323 | ) | |
| (5,471 | ) | |
| (14,511 | ) | |
| (18,810 | ) |
Income tax expense | |
| 84 | | |
| 19 | | |
| 168 | | |
| 40 | |
Net loss | |
$ | (4,407 | ) | |
| (5,490 | ) | |
| (14,679 | ) | |
| (18,850 | ) |
Comparison for the three months ended September
30, 2023 and 2022:
Revenues
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Revenues | |
$ | 11,767 | | |
$ | 7,864 | | |
$ | 3,903 | | |
| 50 | % |
Revenues increased $3.9 million
to $11.8 million during the three months ended September 30, 2023, as compared to $7.9 million during the three months ended September
30, 2022. The increase was primarily attributable to a 47% increase in the average number of clinicians in service in addition to a 2%
increase in ARPU. The increase in clinicians in service was driven predominantly by our existing Health Enterprises adding physicians.
Dollar-based net revenue retention was 157% in the three months ended September 30, 2023. Increases in revenue were also attributable
to growth coming from new physician practice groups and growth of our Notes business.
Cost of Revenues and Gross Margin
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Cost of revenues | |
$ | 5,937 | | |
$ | 4,274 | | |
$ | 1,663 | | |
| 39 | % |
Cost of revenues increased
$1.7 million to $5.9 million during the three months ended September 30, 2023, as compared to $4.3 million during the three months ended
September 30, 2022. The increase was primarily attributable to the $1.5 million increase in MDS costs to support the clinicians in service
growth. Additionally, cloud hosting costs and depreciation and amortization from hardware spend grew $0.1 million as we have utilized
more Automatic Speech Recognition (“ASR”), consumed more cloud hosting as our clinician count increased, and purchased more
devices. As a result of operating efficiencies in our MDS operations, cloud hosting, and customer support, our gross margin was 49.5%
during the three months ended September 30, 2023, as compared to 45.7% during the three ended September 30, 2022.
General and Administrative Expenses
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
General and administrative | |
$ | 4,568 | | |
$ | 4,136 | | |
$ | 432 | | |
| 10 | % |
General and administrative
expenses increased $0.4 million to $4.6 million during the three months ended September 30, 2023, as compared to $4.1 million during the
three months ended September 30, 2022. The increase was attributable to a $0.4 million increase in higher salary and salary-related costs
both from current employees as raises were delayed until July and from growth in headcount. In addition, there was a $0.1 million increase
of facilities costs due to increased rent costs from the expansion into a new building in Bangladesh. Lastly there was a $0.1 million
increase in software expenses driven by additional users of existing software and more software applications. Increases were offset by
$0.1 million of savings from lower insurance premiums and $0.1 million decline in recruiting fees.
Sales and Marketing Expenses
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Sales and marketing | |
$ | 2,729 | | |
$ | 2,304 | | |
$ | 425 | | |
| 18 | % |
Sales and marketing expenses
increased $0.4 million to $2.7 million during the three months ended September 30, 2023, as compared to $2.3 million during the three
months ended September 30, 2022. An increase of $0.2 million was attributable to added headcount of our Customer Success team to support
expansion sales and support of our growing customer base, while the growth of our customer onboarding team contributed another $0.1 million
increase to expenses. The remaining $0.1 million of growth was driven from increased spending on advertising and public relation expenses.
Research and Development Expenses
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Research and development | |
$ | 2,936 | | |
$ | 2,608 | | |
$ | 328 | | |
| 13 | % |
Research and development
expenses increased $0.3 million to $2.9 million during the three months ended September 30, 2023, as compared to $2.6 million during the
three months ended September 30, 2022. Research and development expenses increased by $0.3 million mainly due to additional investments
in engineering and product plus an incremental $0.1 million of spend on training. This was offset by a $0.2 million capitalization of
software expenses from the application development of Augmedix Go.
Other Income (Expenses)
| |
Three Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Interest expense | |
$ | (642 | ) | |
$ | (316 | ) | |
$ | (326 | ) | |
| 103 | % |
Interest income | |
| 288 | | |
| 59 | | |
| 229 | | |
| 388 | % |
Change in fair value of warrant liability | |
| (36 | ) | |
| — | | |
| (36 | ) | |
| 100 | % |
Other income | |
| 470 | | |
| 244 | | |
| 226 | | |
| 93 | % |
| |
$ | 80 | | |
$ | (13 | ) | |
$ | 93 | | |
| (715 | )% |
Our interest expense increased
$0.3 million to $0.6 million during the three months ended September 30, 2023, compared to $0.3 million during the three months ended
September 30, 2022. The increase was attributable to a higher interest rate on our debt due to the higher Federal Funds rate combined
with an increase in our total debt outstanding. Our interest income increased by $0.2 million to $0.3 million during the three months
ended September 30, 2023 compared to $0.1 million during the three months ended September 30, 2022, due to higher interest rates and the
increased use of money market funds.
Other income increased $0.3
million to $0.5 million in the three months ended September 30, 2023 compared to $0.2 million during the three months ended September
30, 2023. The increase was primarily due to a $0.3 million incentive payment received by the Company from the Bangladesh Government for
investments made in Bangladesh.
Comparison for the nine months ended September
30, 2023 and 2022:
Revenues
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Revenues | |
$ | 32,175 | | |
$ | 22,182 | | |
$ | 9,993 | | |
| 45 | % |
Revenues increased 45%, or
$10.0 million, to $32.2 million during the nine months ended September 30, 2023, as compared to $22.2 million during the nine months ended
September 30, 2022. The increase was primarily attributable to a 46% increase in the average number of clinicians in service and slightly
offset by a nominal decrease in ARPU driven by a larger mix of emergency department shift-based clinicians. The increase in the average
number of clinicians in service was driven predominately by our existing Health Enterprises adding physicians, as well as growth in the
number of clinicians using Augmedix Notes, and the addition of new customers. Dollar-based net revenue retention was 147% in the nine
months ended September 30, 2023.
Cost of Revenues and Gross Margin
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Cost of revenues | |
$ | 16,894 | | |
$ | 12,277 | | |
$ | 4,617 | | |
| 38 | % |
Cost of revenues increased
$4.6 million to $16.9 million during the nine months ended September 30, 2023, as compared to $12.3 million during the nine months ended
September 30, 2022. The increase was primarily attributable to a $4.3 million increase in MDS costs driven by additional clinicians in
service. In addition, cloud hosting costs increased by $0.2 million due to the addition of new clinicians, and higher spend on consumption-based
technology to drive automation. Lastly, there was a $0.2 million increase in hardware depreciation due to the growth of clinicians. Gross
margin for the nine months ended September 30, 2023 was 47.5%, as compared to 44.7% in the nine months ended September 30, 2022.
General and Administrative Expenses
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
General and administrative | |
$ | 13,535 | | |
$ | 12,355 | | |
$ | 1,180 | | |
| 10 | % |
General and administrative
expenses increased $1.2 million to $13.5 million during the nine months ended September 30, 2023, as compared to $12.4 million during
the nine months ended September 30, 2022. The increase was attributable to a $0.3 million increase in legal fees associated with the debt
amendment and equity raise. There was also a $0.3 million increase associated with higher Board of Director fees and our HITRUST certification
costs, as well as $0.2 million of facilities costs associated with the new building in Bangladesh. The remaining $0.4 million was attributable
to an increase in salary and salary-related expenses both from growth in headcount and from raises implemented for US employees in July
2023.
Sales and Marketing Expenses
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Sales and marketing | |
$ | 7,941 | | |
$ | 6,944 | | |
$ | 997 | | |
| 14 | % |
Sales and marketing expenses increased $1.0 million to $7.9 million
during the nine months ended September 30, 2023, as compared to $6.9 million during the nine months ended September 30, 2022. The increase
was attributable to a $0.5 million of additional costs due to a larger customer onboarding team to support the growing number of clinicians
launching our services, $0.2 million of additional spending in marketing and public relations, and a $0.4 million increase in the combined
salaries of the Customer Success Management and the Analytics & Insights teams, partially offset by a $0.2 million decrease in salaries
of the sales team.
Research and Development Expenses
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Research and development | |
$ | 8,236 | | |
$ | 7,537 | | |
$ | 699 | | |
| 9 | % |
Research and development
expenses increased $0.7 million to $8.2 million during the nine months ended September 30, 2023, as compared to $7.5 million during the
nine months ended September 30, 2022. The increase was primarily attributable to a $0.7 million investment into engineering and product
headcount along with higher salaries, offset by $0.4 million of capitalization of application development costs for Augmedix Go.
The remaining $0.4 million expense increase was driven by higher training costs to grow our MDS capacity to meet the service needs of
our larger base of clinician users.
Other Income (Expenses)
| |
Nine Months Ended September 30, | | |
$ | | |
% | |
(in thousands) | |
2023 | | |
2022 | | |
Change | | |
Change | |
Interest expense | |
$ | (1,608 | ) | |
$ | (1,302 | ) | |
$ | (306 | ) | |
| (23 | )% |
Interest income | |
| 726 | | |
| 68 | | |
| 658 | | |
| 968 | % |
Loss on debt extinguishment | |
| — | | |
| (1,097 | ) | |
| 1,097 | | |
| (100 | )% |
Change in fair value of warrant liability | |
| (105 | ) | |
| — | | |
| (105 | ) | |
| (100 | )% |
Other | |
| 907 | | |
| 452 | | |
| 455 | | |
| 101 | % |
| |
$ | (80 | ) | |
$ | (1,879 | ) | |
$ | 1,799 | | |
| (96 | )% |
Our interest expense increased
$0.3 million to $1.6 million during the nine months ended September 30, 2023, compared to $1.3 million during the nine months ended September
30, 2022, The increase was attributable to a higher interest rate on our debt due to the higher Federal Funds rate combined with an increase
of our total debt outstanding. Our interest income increased by $0.7 million to $0.7 million during the nine months ended September 30,
2023 due to the increased use of money market funds and higher interest rates. There was a $1.1 million decrease in loss on debt extinguishment
in the nine months ended September 30, 2023 versus September 30, 2022 due to the refinancing of our debt facility last year. There was
a $0.1 million decrease in the nine months ending September 30, 2023 versus September 30, 2022 due to change in fair value of our warrant
liability.
Other income increased $0.5
million in the nine months ended September 30, 2023 mainly due to a $0.2 million increase in Bangladesh government incentive payments
received by the Company for investments made in Bangladesh and a $0.3 million gain on foreign exchange.
Additionally, there is no
assurance if we require additional future financing that such financing will be available on terms that are acceptable to us, or at all.
Liquidity and Capital Resources
Our primary sources of liquidity are cash raised from sales of common
stock, preferred stock previous to 2020, and cash from equity financings and borrowings under various facilities, which are further described
below. As of September 30, 2023, we had cash resources of $22.3 million which includes $0.7 million of restricted cash to secure our credit
card facility balances, to collateralize a letter of credit in the name of our landlord pursuant to an operating lease, and for a post-employment
savings fund established for the benefit of eligible Bangladesh employees. Since Augmedix’s inception in 2013 until today, we have
financed our operations primarily through the private and public sale of approximately $205 million of preferred and common stock and
from various debt arrangements. As described in Note 1 of our unaudited interim condensed consolidated financial statements, we have incurred
recurring losses and negative cash flows from operations since inception and have an accumulated deficit at September 30, 2023 of $140.5
million. We have relied on debt and equity financing to fund operations to date and we expect losses and negative cash flows to continue,
primarily as a result of continued research, development and marketing efforts. Our cash balance will provide sufficient resources to
meet working capital needs for over twelve months from the filing date of the September 30, 2023 Form 10-Q. Over the longer term, if we
do not generate sufficient revenue from new and existing products, additional debt or equity financing may be required along with a reduction
in expenditures.
The
following table summarizes our sources and uses of cash for each of the periods presented:
| |
Nine Months Ended September 30, | |
(in thousands) | |
2023 | | |
2022 | |
Cash (used in) provided by: | |
| | |
| |
Operating activities | |
$ | (14,468 | ) | |
$ | (12,387 | ) |
Investing activities | |
| (1,912 | ) | |
| (816 | ) |
Financing activities | |
| 16,989 | | |
| (1,244 | ) |
Effects of exchange rate changes on cash and restricted cash | |
| (311 | ) | |
| (143 | ) |
Net increase (decrease) in cash, cash equivalents and restricted cash | |
$ | 298 | | |
$ | (14,590 | ) |
Operating Activities
Cash used in operating activities
was $14.5 million and $12.4 million for the nine months ended September 30, 2023 and 2022, respectively. Cash used in operating activities
during the nine months ended September 30, 2023 principally resulted from our net loss of $14.7 million, which includes non-cash charges
of $3.9 million, and increase in working capital of $3.6 million.
Cash used in operating activities
during the nine months ended September 30, 2022 principally resulted from our net loss of $18.9 million, which includes non-cash charges
of $4.3 million, and decreases in working capital of $2.2 million.
Investing Activities
Cash used in investing activities
was $1.9 million and $0.8 million for the nine months ended September 30, 2023 and 2022, respectively. Cash used in investing activities
resulted from capital expenditures of property and equipment for both periods presented.
Financing Activities
Cash provided by financing
activities during the nine months ended September 30, 2023 of $17.0 million principally resulted from $11.8 million from issuance of common
stock, and warrants, net of issuance costs, $5.0 million in debt proceeds, and $0.2 million from the exercise of stock options.
Cash used in financing activities
during the nine months ended September 30, 2022 of $1.2 million principally resulted from $15.0 million of debt proceeds which was offset
by $16.1 million in repayment of an existing debt agreement, and exit fees and $0.1 million in payments for financing costs related to
the new debt arrangement.
Contractual Obligations and Commitments
The following summarizes
our significant contractual obligations as of September 30, 2023:
| |
Payments due by period | |
| |
| | |
Less than | | |
| | |
| | |
More than | |
(in thousands) | |
Total | | |
1 year | | |
1-3 years | | |
4-5 years | | |
5 years | |
Long-term debt obligations (excluding interest) | |
| 21,000 | | |
| 10,000 | | |
| 11,000 | | |
| — | | |
| — | |
Operating lease obligations | |
| 4,041 | | |
| 360 | | |
| 2,831 | | |
| 850 | | |
| — | |
Cloud computing obligation | |
| 1,300 | | |
| 1,300 | | |
| — | | |
| — | | |
| — | |
Total | |
$ | 26,341 | | |
$ | 11,660 | | |
$ | 13,831 | | |
$ | 850 | | |
$ | — | |
Off-Balance Sheet Arrangements
As of September 30, 2023,
we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured
finance or variable interest entities, which would have been established for the purpose of facilitating off-balance sheet
arrangements or other contractually narrow or limited purposes.
Critical Accounting Policies and Estimates
Other than as described under
Note 2 to our unaudited interim condensed consolidated financial statements, the Critical Accounting Policies and Significant Judgments
and Estimates included in our Form 10-K for the year ended December 31, 2022, filed with the SEC on April 17, 2023, have not
materially changed.
JOBS Act Accounting Election
We are an emerging growth
company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards
issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use
this extended transition period for complying with new or revised accounting standards that have different effective dates for public
and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively
and irrevocably opt out of the extended transition period provided in the JOBS Act. We have elected to early adopt certain new accounting
standards, as described in Note 2 of our consolidated financial statements. As a result, these financial statements may not be comparable
to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Issued Accounting Pronouncements
A description of recently
issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to
our unaudited financial statements appearing elsewhere in this Quarterly Report.
Item
3. Quantitative and Qualitative Disclosures about Market Risk.
We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item
4. Controls and Procedures.
Management’s
Evaluation of our Disclosure Controls and Procedures
Disclosure
controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our
reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in
the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure
that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated
to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
We
do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and
procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives.
Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits
must be considered relative to their costs. The design of disclosure controls and procedures also is based partly on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions.
As
of September 30, 2023, as required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial
Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon
their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective at the reasonable assurance level as of such date, due to
the material weakness in our internal control over technical accounting analyses, and the regular review and application of accounting
policies, as the Company grew and its operations changed. Notwithstanding the identified material weakness, management has concluded that
the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, the Company’s financial
position, results of operations, and cash flows for the periods disclosed in accordance with GAAP.
Remediation Efforts
to Address the Material Weakness
A
material weakness in our internal control over the application of accounting policies was identified as of September 30, 2022. A material
weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.
The material weakness identified was a lack of sufficient resources in our finance function to meet our financial reporting requirements.
This material weakness resulted in insufficient management review of accounting policies as our company grew. Management continues to
review and make necessary changes to the overall design of our internal control environment, including implementing additional internal
controls over the annual review of all relevant accounting policies, particularly in areas where our operations have changed. We will
add additional resources and expertise to our finance function to enhance the effectiveness of internal controls over financial reporting.
The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time
and management has concluded, through testing, that these controls are operating effectively. Although we plan to complete this remediation
process as quickly as possible, we cannot estimate at this time how long it will take.
Changes in Internal Control over Financial
Reporting
During the quarter ended
September 30, 2023, there have been no changes in our internal control over financial reporting as such term is defined in Rule 13a-15(f)
and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
PART II - OTHER INFORMATION
Item
1. Legal Proceedings.
We are not a party to any material pending legal
proceedings. From time to time, we may become involved in lawsuits and legal proceedings that arise in the ordinary course of business.
Item
1A. Risk Factors.
In addition to the other information set forth
in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors”
of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on April 17, 2023. There have been no
material changes in reported risk factors from the information reported in our Annual Report on Form 10-K for the fiscal year ended December
31, 2022.
Item
2. Unregistered sales of equity securities and use of proceeds.
None.
Item
3. Defaults upon senior securities.
Not applicable.
Item
4. Mine safety disclosures.
Not applicable.
Item
5. Other information.
During the three months ended September
30, 2023, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the
purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule
10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
Item
6. Exhibits.
The following is a list of exhibits filed as part
of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits
incorporated by reference, the location of the exhibit in the previous filing is indicated.
Exhibit
Number |
|
Description |
2.1 |
|
Agreement
and Plan of Merger and Reorganization among Malo Holdings Corporation, a Delaware corporation, August Acquisition Corp, a Delaware
corporation, and Augmedix, Inc., a Delaware corporation (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K
filed with the SEC on October 9, 2020). |
3.1 |
|
Restated
certificate of incorporation, filed with the Secretary of State of the State of Delaware on October 5, 2020 (incorporated by reference
to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on October 9, 2020) |
3.2 |
|
Restated
Bylaws (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed with the SEC on October 9, 2020) |
10.1* |
|
Fourth
Omnibus Amendment, entered into on July 11, 2023, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity
Health Medical Foundation, and Pacific Central Coast Health Centers (incorporated by reference to Exhibit 10.1 to the Current Report
on Form 8-K filed with the SEC on July 14, 2023). |
10.2* |
|
Fifth
Omnibus Amendment, entered into on October 10, 2023, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health,
Dignity Health Medical Foundation, and Pacific Central Coast Health Centers (incorporated by reference to Exhibit 10.1 to the Current
Report on Form 8-K filed with the SEC on October 13, 2023). |
10.3 |
|
Amendment
to Sublease, by and between Augmedix Operating Corp. and Turo Inc., dated October 31, 2023 (incorporated by reference to Exhibit
10.1 to the Current Report on Form 8-K filed with the SEC on November 6, 2023) |
31.1+ |
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2+ |
|
Certification
of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1# |
|
Certification
of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2# |
|
Certification
of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS |
|
Inline
XBRL Instance Document. |
101.SCH |
|
Inline
XBRL Taxonomy Extension Schema Document. |
101.CAL |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document. |
104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
# |
This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
+ |
Filed herewith. |
|
|
* |
Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
AUGMEDIX, INC.
(Registrant) |
|
|
|
Date: November 13, 2023 |
By: |
/s/ Emmanuel Krakaris |
|
Name: |
Emmanuel Krakaris |
|
Title: |
President, Chief Executive Officer and Secretary |
|
|
(Principal Executive Officer) |
|
|
|
Date: November 13, 2023 |
By: |
/s/ Paul Ginocchio |
|
Name: |
Paul Ginocchio |
|
Title: |
Chief Financial Officer |
|
|
(Principal Accounting and Financial Officer) |
39
0.10
0.15
0.35
0.50
37412238
37426751
42236063
45520893
false
--12-31
Q3
0001769804
0001769804
2023-01-01
2023-09-30
0001769804
2023-11-06
0001769804
2023-09-30
0001769804
2022-12-31
0001769804
2023-07-01
2023-09-30
0001769804
2022-07-01
2022-09-30
0001769804
2022-01-01
2022-09-30
0001769804
us-gaap:CommonStockMember
2022-12-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001769804
us-gaap:RetainedEarningsMember
2022-12-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-12-31
0001769804
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001769804
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-01-01
2023-03-31
0001769804
2023-01-01
2023-03-31
0001769804
us-gaap:CommonStockMember
2023-03-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001769804
us-gaap:RetainedEarningsMember
2023-03-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001769804
2023-03-31
0001769804
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001769804
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-04-01
2023-06-30
0001769804
2023-04-01
2023-06-30
0001769804
us-gaap:CommonStockMember
2023-06-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001769804
us-gaap:RetainedEarningsMember
2023-06-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-06-30
0001769804
2023-06-30
0001769804
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001769804
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-07-01
2023-09-30
0001769804
us-gaap:CommonStockMember
2023-09-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001769804
us-gaap:RetainedEarningsMember
2023-09-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-09-30
0001769804
us-gaap:CommonStockMember
2021-12-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001769804
us-gaap:RetainedEarningsMember
2021-12-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-12-31
0001769804
2021-12-31
0001769804
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001769804
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-01-01
2022-03-31
0001769804
2022-01-01
2022-03-31
0001769804
us-gaap:CommonStockMember
2022-03-31
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001769804
us-gaap:RetainedEarningsMember
2022-03-31
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-03-31
0001769804
2022-03-31
0001769804
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001769804
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-04-01
2022-06-30
0001769804
2022-04-01
2022-06-30
0001769804
us-gaap:CommonStockMember
2022-06-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001769804
us-gaap:RetainedEarningsMember
2022-06-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-06-30
0001769804
2022-06-30
0001769804
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001769804
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-07-01
2022-09-30
0001769804
us-gaap:CommonStockMember
2022-09-30
0001769804
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001769804
us-gaap:RetainedEarningsMember
2022-09-30
0001769804
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-09-30
0001769804
2022-09-30
0001769804
augx:SalesRevenueMember
2023-09-30
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-09-30
0001769804
augx:CustomerThreeMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-07-01
2023-09-30
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0001769804
augx:CustomerThreeMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-07-01
2022-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-07-01
2022-09-30
0001769804
augx:CustomerThreeMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-07-01
2022-09-30
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-09-30
0001769804
augx:CustomerThreeMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-01-01
2022-09-30
0001769804
augx:CustomerFourMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-01-01
2023-09-30
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2023-09-30
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CreditConcentrationRiskMember
2022-01-01
2022-12-31
0001769804
augx:CustomerOneMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-12-31
0001769804
augx:CustomerTwoMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-12-31
0001769804
2022-01-01
2022-12-31
0001769804
augx:CommonStockWarrantsMember
2023-01-01
2023-09-30
0001769804
augx:CommonStockWarrantsMember
2022-01-01
2022-09-30
0001769804
us-gaap:StockOptionMember
2023-01-01
2023-09-30
0001769804
us-gaap:StockOptionMember
2022-01-01
2022-09-30
0001769804
augx:RSUMember
2023-01-01
2023-09-30
0001769804
augx:RSUMember
2022-01-01
2022-09-30
0001769804
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001769804
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001769804
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001769804
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-09-30
0001769804
us-gaap:FairValueInputsLevel2Member
2023-01-01
2023-09-30
0001769804
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-09-30
0001769804
us-gaap:FairValueInputsLevel1Member
2022-09-30
0001769804
us-gaap:FairValueInputsLevel2Member
2022-09-30
0001769804
us-gaap:FairValueInputsLevel3Member
2022-09-30
0001769804
2022-09-01
2022-09-30
0001769804
us-gaap:FairValueInputsLevel1Member
2022-09-01
2022-09-30
0001769804
us-gaap:FairValueInputsLevel2Member
2022-09-01
2022-09-30
0001769804
us-gaap:FairValueInputsLevel3Member
2022-09-01
2022-09-30
0001769804
augx:ComputerHardwareSoftwareAndEquipmentMember
2023-09-30
0001769804
augx:ComputerHardwareSoftwareAndEquipmentMember
2022-12-31
0001769804
us-gaap:LeaseholdImprovementsMember
2023-09-30
0001769804
us-gaap:LeaseholdImprovementsMember
2022-12-31
0001769804
augx:CapitalizedInternaluseSoftwareCostsMember
2023-09-30
0001769804
augx:CapitalizedInternaluseSoftwareCostsMember
2022-12-31
0001769804
us-gaap:FurnitureAndFixturesMember
2023-09-30
0001769804
us-gaap:FurnitureAndFixturesMember
2022-12-31
0001769804
us-gaap:ConstructionInProgressMember
2023-09-30
0001769804
us-gaap:ConstructionInProgressMember
2022-12-31
0001769804
augx:EastwardLoanAgreementMember
2021-03-01
2021-03-25
0001769804
augx:EastwardLoanAgreementMember
2021-03-31
0001769804
augx:EastwardLoanAgreementMember
2023-09-30
0001769804
augx:SubAgreementMember
2023-01-01
2023-09-30
0001769804
augx:SVBLoanAndSecurityAgreementMember
2023-01-01
2023-09-30
0001769804
augx:SVBLoanAndSecurityAgreementMember
2023-09-30
0001769804
augx:SVBLoanAndSecurityAgreementMember
2023-06-13
0001769804
augx:SVBLoanAndSecurityAgreementMember
2023-07-13
0001769804
2023-12-31
0001769804
augx:HCAHealthcareIncMember
2023-04-18
2023-04-19
0001769804
2023-04-18
2023-04-19
0001769804
2023-04-19
0001769804
augx:PrefundedWarrantsMember
2023-04-19
0001769804
augx:BreakevenWarrantsMember
2023-04-19
0001769804
2023-06-11
2023-06-13
0001769804
2023-06-13
0001769804
us-gaap:PreferredStockMember
2023-09-30
0001769804
augx:October252024Member
2023-12-31
0001769804
augx:June112025Member
2023-12-31
0001769804
augx:November132025Member
2023-12-31
0001769804
augx:July282027Member
2023-12-31
0001769804
augx:August282028Member
2023-12-31
0001769804
augx:May42029Member
2023-12-31
0001769804
augx:September22029Member
2023-12-31
0001769804
augx:AprilOneNineTwoZeroThreeZeroMember
2023-12-31
0001769804
augx:June132030Member
2023-12-31
0001769804
augx:PerpetualMember
2023-01-01
2023-12-31
0001769804
augx:PerpetualMember
2023-12-31
0001769804
augx:EquityIncentivePlanMember
2023-01-01
2023-09-30
0001769804
us-gaap:StockOptionMember
2023-01-01
2023-09-30
0001769804
us-gaap:StockOptionMember
2022-01-01
2022-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2023-01-01
2023-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2023-09-30
0001769804
us-gaap:OptionMember
2023-01-01
2023-09-30
0001769804
us-gaap:OptionMember
2023-09-30
0001769804
augx:StockOptionsSARsMember
2023-07-01
2023-09-30
0001769804
augx:StockOptionsSARsMember
2022-07-01
2022-09-30
0001769804
augx:StockOptionsSARsMember
2023-01-01
2023-09-30
0001769804
augx:StockOptionsSARsMember
2022-01-01
2022-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2023-07-01
2023-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2022-07-01
2022-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2022-01-01
2022-09-30
0001769804
augx:StockOptionsSARsMember
2022-12-31
0001769804
augx:StockOptionsSARsMember
2023-01-01
2023-09-30
0001769804
augx:StockOptionsSARsMember
2023-09-30
0001769804
us-gaap:RestrictedStockUnitsRSUMember
2022-12-31
0001769804
2021-06-30
0001769804
2015-12-31
0001769804
augx:BangladeshSubsidiaryMember
2023-07-01
2023-09-30
0001769804
augx:BangladeshSubsidiaryMember
2022-07-01
2022-09-30
0001769804
augx:GratuityFundMember
2023-01-01
2023-09-30
0001769804
augx:BangladeshSubsidiaryMember
2023-01-01
2023-09-30
0001769804
augx:BangladeshSubsidiaryMember
2023-09-30
0001769804
augx:BangladeshSubsidiaryMember
2022-12-31
0001769804
augx:IndiaSubsidiaryMember
2023-07-01
2023-09-30
0001769804
augx:IndiaSubsidiaryMember
2023-01-01
2023-09-30
0001769804
augx:IndiaSubsidiaryMember
2023-09-30
0001769804
srt:BoardOfDirectorsChairmanMember
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:SubsequentEventMember
2023-10-17
2023-10-17
0001769804
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:SubsequentEventMember
2023-10-17
0001769804
us-gaap:StockAppreciationRightsSARSMember
2023-10-17
2023-10-17
0001769804
us-gaap:StockAppreciationRightsSARSMember
2023-10-17
0001769804
us-gaap:SubsequentEventMember
2023-10-30
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
In connection with the Quarterly Report of Augmedix,
Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that:
In connection with the Quarterly Report of Augmedix,
Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that: